RTI Biologics, Inc. (RTIX) Reports In-Line Q1 EPS; Guides Q211
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Price: $3.14 --0%
Financial Fact:
Foreign exchange (loss) gain: -67K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Foreign exchange (loss) gain: -67K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
RTI Biologics, Inc. (Nasdaq: RTIX) reported Q1 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $40.6 million versus the consensus estimate of $38.32 million.
Sees Q2 2011 EPS of $0.03, versus the consensus of $0.03. Sees Q2 2011 revenue of $40-$41 million, versus the consensus of $40.03 million.
Sees Q2 2011 EPS of $0.03, versus the consensus of $0.03. Sees Q2 2011 revenue of $40-$41 million, versus the consensus of $40.03 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
- Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
